Latest Breaking News On - Utilizing urogen - Page 1 : comparemela.com

UroGen Pharma Announces Date for ENVISION Data, New Long-Term Jelmyto Durability Data, and Reports 2024 First Quarter Financial Results and Business Highlights

UroGen Pharma Announces Date for ENVISION Data, New Long-Term Jelmyto Durability Data, and Reports 2024 First Quarter Financial Results and Business Highlights
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

San antonioUnited statesUrogen pharmaLiz barrettUrogen rtgelDrug administrationAmerican urological associationUrogen pharma ltdCompany investigational new drugChief executive officerRecent business highlightsNew drug applicationInvestigational new drugPrepaid forward obligationLong term debtPharmakon advisors

UroGen Initiates Submission of a Rolling NDA to the FDA for UGN-102

UroGen Initiates Submission of a Rolling NDA to the FDA for UGN-102
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Vincent perroneUrogen rtgelCindy romanoLiz barrettUrogen pharma ltdCorporate communicationsDrug administrationGen pharmaNew drug applicationUtilizing urogenPrivate securities litigation reform actRisk factorsQuarterly reportInvestor relationsUrogen pharma

UroGen Initiates Submission of a Rolling NDA to the FDA for UGN-102

UroGen Initiates Submission of a Rolling NDA to the FDA for UGN-102
eagletribune.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from eagletribune.com Daily Mail and Mail on Sunday newspapers.

United statesVincent perroneCindy romanoLiz barrettUrogen rtgelCorporate communicationsUrogen pharma ltdDrug administrationGen pharmaNew drug applicationUtilizing urogenPrivate securities litigation reform actRisk factorsQuarterly reportUrogen pharmaBusiness wire